Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Corcept Therapeutics Incorporated during the specified Class Period, indicating potential legal issues surrounding the company's stock performance and disclosures [1]. Group 1: Class Action Details - The class action lawsuit is on behalf of investors who purchased Corcept common stock between October 31, 2024, and December 30, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must be appointed by April 21, 2026, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. Group 3: Case Specifics - The lawsuit claims that Corcept misrepresented the strength of clinical trials for relacorilant, suggesting it was a strong candidate for FDA approval, while the FDA had raised concerns about the clinical evidence [5]. - The defendants allegedly assured investors that there were no impediments to the New Drug Application (NDA) approval, which was later contradicted by the FDA's concerns [5]. - When the true situation regarding the NDA was revealed, investors reportedly suffered damages [5].

Core Viewpoint - A class action lawsuit has been filed against Ostin Technology Group Co., Ltd. for alleged securities fraud during the class period from May 11, 2025, to June 26, 2025, with significant losses reported by investors [2][5]. Allegation Details - The lawsuit alleges that on September 12, 2025, a criminal indictment was unsealed against Ostin's co-CEO Lai Kui Sen and financial advisor Yan Zhao, charging them with conspiracy to commit securities fraud and wire fraud, resulting in over $110 million in illicit proceeds [5]. - The complaint claims that starting in April 2025, Lai Kui Sen and co-conspirators executed fraudulent securities offerings, allowing them to acquire Ostin shares at minimal or no cost, while simultaneously inflating the stock price through deceptive promotional campaigns [5]. - Ostin's market capitalization reportedly increased from approximately $22 million to over $1 billion during the class period, with the stock price peaking at $9.40 on June 26, 2025, before a significant selloff led to a loss of over $950 million in market capitalization in one day [5]. Next Steps - Investors who purchased Ostin shares and suffered losses are encouraged to contact Bragar Eagel & Squire, P.C. for more information regarding their rights and potential claims [4].

Core Viewpoint - The Navan class action lawsuit alleges that Navan, Inc. and its executives misled investors regarding the company's financial health and future expenses during its IPO, leading to significant stock price declines after the IPO [1][3][4]. Company Overview - Navan, Inc. operates an AI-powered software platform aimed at simplifying travel and expense management for users, customers, and suppliers [2]. IPO Details - Navan conducted its IPO on October 31, 2025, issuing nearly 37 million shares at an offering price of $25.00 per share [2]. Allegations of Misleading Information - The lawsuit claims that the IPO offering documents were materially false or misleading, particularly regarding a 39% increase in sales and marketing expenses shortly after the IPO, which was necessary to sustain revenue growth [3]. Financial Impact - On December 15, 2025, Navan reported a significant increase in sales and marketing expenses to nearly $95 million, up from $68.5 million in the previous quarter, which contributed to a nearly 12% drop in stock price following the announcement [4]. - By the time the lawsuit commenced, Navan's stock price had fallen to as low as $9.20 per share, representing a decline of nearly 63% from the IPO price [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Navan common stock during the IPO to seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone, marking its fourth 1 ranking in the past five years [7].

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Zynex, Inc. (OTCMKTS: ZYXIQ) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zynex securities between February 25, 2021 and December 15, 2025, both dates ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BlackRock TCP Capital Corp. ("BlackRock TCP" or the "Company") (NASDAQ: TCPC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BlackRock TCP investors who were adversely affected by alleged securities fraud between November 6, 2024 and January 23, 2026. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/bl ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in CoreWeave, Inc. ("CoreWeave, Inc." or the "Company") (NASDAQ: CRWV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of CoreWeave, Inc. investors who were adversely affected by alleged securities fraud between March 28, 2025 and December 15, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/coreweave-i ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in REGENXBIO Inc. ("REGENXBIO" or the "Company") (NASDAQ: RGNX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of REGENXBIO investors who were adversely affected by alleged securities fraud between February 9, 2022 and January 27, 2026. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/regenxbio-inc-lawsuit-s ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Richtech Robotics Inc. ("Richtech" or the "Company") (NASDAQ: RR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Richtech investors who were adversely affected by alleged securities fraud between January 27, 2026 and January 29, 2026. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/richtech-lawsuit-su ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in PayPal Holdings, Inc. ("PayPal" or the "Company") (NASDAQ: PYPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PayPal investors who were adversely affected by alleged securities fraud between February 25, 2025 and February 2, 2026. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/paypal-holdings-inc-l ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Fermi Inc. ("Fermi Inc." or the "Company") (NASDAQ: FRMI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fermi Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Fermi: (a) common stock pursuant and/or traceable to the registration statement and prospectus i ...